Press Releases

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform. The platform was developed by Aptar’s drug services company, Nanopharm. If validated, SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes – removing a major barrier f

PODO Therapeutics, a precision medicine-focused biotechnology company, today announced that it will present its latest research findings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30 in the United States. The company will showcase two poster presentations that highlight its innovative platform that uses cancer organoids co-cultured with immune cells to accurately predict individual patient responses to immunotherapies and radi

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a New Drug Application (NDA) for its new generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of adult and adolescent patients (12 to 18 years old) with advanced solid tumors harboring NTRK gene fusions. In the registrational

A  first in human proof of concept phase I clinical study of VAS-101 in sickle cell disease (SCD) is underway. The study is being conducted by the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Florida, under the supervision of the principal investigator, Dr. Gershwin Blyden. Ten (10) patients with sickle cell disease will be treated with VAS-101 twice per week over 4 weeks for a total of 8 treatments; their blood will be drawn weekly. Five (5) patients will

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications, today announces the unveiling of novel pharmacodynamic (PD) blood markers for its lead compound, Aramchol, the industry's most clinically advanced SCD1 inhibitor. These newly identified biomarkers shed fresh light on Aramchol's potential far beyond its role in NASH (MASH) therapy—offering a deeper u

Rein Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines. The manuscript, titled "Caveolin Scaffolding Doma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment of adult patients with advanced triple-negative breast cancer (TNBC) and results from an early Phase I/II clinical study of sac-TMT for the treatment of adult patients with advanced non-s all-cell lung cancer (NSCLC) were published in the top international medical

Exicure, Inc. today shared updates on its lead asset, GPC-100, a small molecule CXCR4 inhibitor. Exicure, Inc. is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that GPC-100, when paired with modern AML treatment regimens, can further improve outcomes in this high unmet need clinical indication. A Phase 1 chemosensitization study involving 15 patients with relapsed or refractory AML was previously conducted by Taigen, the original de

Today, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States. This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jo

Halozyme Therapeutics, Inc. today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART® Hytrulo prefilled syringe for se